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Abstract
The key to therapeutic success with yeast infections is an early onset of antifungal treatment with an appropriate drug regimen. To do
this, yeast species identiﬁcation is necessary, but conventional biochemical and morphological approaches are time-consuming. The
recent arrival of biophysical methods, such as matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS), in routine diagnostic laboratories holds the promise of signiﬁcantly speeding up this process. In this study, two commercially
available MALDI-TOF MS species identiﬁcation systems were evaluated for application in clinical diagnostics, using a geographically
diverse collection of 1192 clinical yeast and yeast-like isolates. The results were compared with those of the classical differentiation
scheme based on microscopic and biochemical characteristics. For 95.1% of the isolates, all three procedures consistently gave the cor-
rect species identiﬁcation, but the rate of misclassiﬁcation was greatly reduced in both MALDI-TOF MS systems. Furthermore, several
closely related species (e.g. Candida orthopsilosis/metapsilosis/parapsilosis or Candida glabrata/bracarensis) could be resolved by both
MALDI-TOF MS systems, but not by the biochemical approach. A signiﬁcant advantage of MALDI-TOF MS over biochemistry in the rec-
ognition of isolates novel to the system was observed. Although both MALDI-TOF MS systems employed different approaches in the
database structure and showed different susceptibilities to errors in database entries, these were negligible in terms of clinical useful-
ness. The time-saving beneﬁt of MALDI-TOF MS over biochemical identiﬁcation will substantially improve fungal diagnostics and patient
treatment.
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Yeast infections are a signiﬁcant cause of morbidity and
mortality in critically ill patients, e.g. those undergoing
immunosuppressive therapy, those recovering from surgery,
or in those infected by human imunodeﬁciency virus. Early
therapeutic intervention is critical for successful treatment
of yeast infections [1–3], and the optimal choice of antifun-
gal drugs will ultimately be based on two key factors:
(i) the fungal species and its intrinsic resistance; and (ii) the
result of the in vitro resistance testing of the individual
isolate [4].
The Atlas of Clinical Fungi lists approximately 400 fungal
species with clinical relevance and human pathogenic
potency [5], causing a wide range of clinical symptoms,
ranging from local inﬂammation to life-threatening dissemi-
nated disease. Unfortunately, conventional laboratory differ-
entiation of yeasts, involving, for example, microscopy and
biochemical tests, not only requires up to several days, but
is also cost-intensive and requires extensively trained labo-
ratory personnel. At present, in those cases where classical
methods give unclear results, the isolates need to be
re-analysed by sequencing of species-speciﬁc regions. This is
especially true for rare, potentially emerging yeast patho-
gens that are not identiﬁable by standard tests. Faster
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species identiﬁcation, with rapid determination of the par-
ticular species-speciﬁc intrinsic resistance, would be an
important step forwards in the successful management of
life-threatening fungal diseases.
Recently, matrix-assisted laser desorption ionization time-
of-ﬂight mass spectrometry (MALDI-TOF MS) has been suc-
cessfully introduced for rapid species identiﬁcation of micro-
organisms in the clinical laboratory. With this method, crude
cell extracts can be used to identify the species of a given
isolate by comparison of the mass patterns within approxi-
mately 2–20 kDa with a database containing the patterns of
reference strains. These patterns are highly species-speciﬁc
[6–8], and may even allow subspecies identiﬁcation [9]. As
this process takes only minutes, the introduction of MALDI-
TOF MS into diagnostic laboratories holds the promise of
signiﬁcantly speeding up diagnostic processes while simulta-
neously leading to more accurate identiﬁcation of pathogens
[10,11]. Experimental data also indicate that MALDI-TOF MS
can increase the resolution at which fungal species, such as
different moulds [12–15] and yeasts [9,16], can be differenti-
ated from each other. Therefore, in the clinical laboratory,
MALDI-TOF MS-based differentiation could substantially
improve the quality of and reduce the time needed for the
identiﬁcation of yeasts.
To evaluate the clinical use of the two currently commer-
cially available MALDI-TOF MS systems (MALDI BioTyper2
(Bruker Daltonics, Bremen, Germany) and Saramis (Anagnos-
Tec, Potsdam, Germany)) in yeast identiﬁcation, a collection
of 1192 clinically relevant yeast and yeast-like isolates was
established (Table 1), reﬂecting a species distribution as it is
encountered during clinical routine. Both mass spectrometry
systems were compared with each other and with the classi-




Yeasts were kept either as cryobank stocks (Mast Diagnostica,
Reinfeld, Germany) or as snap-frozen liquid YPD-glycerol
stocks (1% yeast extract, 2% peptone, 1% glucose, 25%
TABLE 1. Species distribution within
the test setSpecies
No. of
isolates Biochemical Biotyper Saramis
Blastoschizomyces capitatus (Geotrichum capitatum) 3 Y N N
Candida albicans 512 Y Y Y
Candida bracarensis 1 N N N
Candida dubliniensis 8 Y Y Y
Candida glabrata 272 Y Y Y
Candida metapsilosis 1 N Y N
Candida orthopsilosis 8 N Y N
Candida parapsilosis 105 Y Y Y
Candida pararugosa 3 N N N
Candida rugosa 8 Y Y N
Candida tropicalis 88 Y Y Y
Candida viswanatii 1 N N N
Clavispora lusitaniae (Candida lusitaniae) 14 Y Y Y
Cryptococcus neoformans 7 Y Y Y
Galactomyces geotrichum (Geotrichum candidum) 1 Na N Y
Geotrichum clavatum 3 Na N N
Issatchenkia orientalis (Candida krusei) 53 Y Y Y
Kluyveromyces marxianus (Candida kefyr) 21 Y Y Y
Kodamaea ohmeri (Candida guilliermondii
var. membranaefaciens)
2 Y Y N
Pichia anomala (Candida pelliculosa) 3 Y Y Y
Pichia cactophila (Candida inconspicua) 7 Y Y Y
Pichia fabianii (Candida fabianii) 7 N N N
Pichia farinosa (Candida cacaoi) 2 Y Y Y
Pichia fermentans (Candida lambica) 1 Y Y Y
Pichia guilliermondii (C. guilliermondii var. guilliermondii) 23 Y Y Y
Pichia jadinii (Candida utilis) 1 Y Y Y
Pichia membranifaciens (Candida valida) 1 Y Y Y
Pichia norvegica (Candida norvegensis) 5 Y Y Y
Rhodotorula mucilaginosa 2 Y Y Y
Saccharomyces cerevisiae 20 Y Y Y
Trichosporon asahii 4 Y Y Y
Yarrowia lipolytica (Candida lipolytica) 1 Y Y Y
Uncharacterized species 4 N N N
Y, represented in the database; N, not represented in the database.
A total of 1192 clinical yeast isolates across the fungal phylum representing 32 known and four uncharacterized spe-
cies were represented in the test set. Teleomorph–anamorph relationships and conspeciﬁc species, as described by
deHoog [5] and others [29,30], necessary to resolve ambiguous nomenclature between the databases used in this
study are given in parentheses.
aGenus level only.
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glycerol), stored at )70C. Once thawed, strains were kept
on agar slants (0.5% peptone (casein), 0.5% peptone (meat),
2% glucose, 2% agar) and re-streaked every 2 weeks. Prior
to any of the experiments, strains were cultivated on Sabou-
raud agar plates (Oxoid, Wesel, Germany) overnight at 35C
or 30C, as appropriate. All chemicals were from Roth
(Karlsruhe, Germany), and media components were from
BD (Heidelberg, Germany).
Strains used in this study
First, we collected all yeast and yeast-like isolates identiﬁed
as human pathogens during routine in-house diagnosis from
October 2008 to March 2009. In addition to these 324 iso-
lates, predominantly obtained from primary sterile material,
310 strains were added from a survey in Sarh, Chad (Ta-
verne-Ghadwal et al., unpublished data). To evaluate the per-
formance of the three methods in the correct identiﬁcation
of less frequent yeasts, we included 275 non-Candida albicans
and non-Candida glabrata strains isolated from our MykoLab-
Net-D strain collection [17]. Also, 22 rare yeast strains
kindly provided by F. Odds (Aberdeen, UK) were added. To
further reduce potential bias in the strain set, we included
261 previously multilocus sequence-typed C. albicans and
C. glabrata isolates obtained from different European labora-
tories (Bader, unpublished data). The collection is summa-
rized in Table 1.
Identiﬁcation procedure
The entire set was tested blindly and independently with all
three procedures, as described below. Species identiﬁcation
was performed by starting with colonies from Sabouraud agar
plates, as recommended by the manufacturers. All
identiﬁcations with results below the deﬁned thresholds were
repeated, and if the species was still undetermined, it was
classiﬁed as ‘unknown’. In cases where the species identiﬁca-
tion did not match in all three test systems, sequencing of the
ITS2 region [18] was used. To ensure the correctness of the
concordant identiﬁcations, where available, two random iso-
lates of each species were subjected to sequencing. No false
identiﬁcations were found in this set (data not shown).
Biochemical fungal differentiation scheme
Fungi were differentiated by the combined use of microscopy
and carbon assimilation testing, using the API 20 C AUX and
ID 32 C systems (bioMe´rieux, Nu¨rtingen, Germany). In
detail, C. albicans and Candida dubliniensis were identiﬁed by
formation of chlamydospores on rice agar (Oxoid) and on
Staib agar (5% pulverized Guizotia abyssinicia seed, 0.1%
glucose, 0.1% KH2PO4, 0.1% creatinine, 1.5% agar) [19,20].
All isolates other than C. albicans were further analysed with
the ID 32 C (V3.0), and in some cases (e.g. to resolve Pichia
norvegica and Pichia cactophila) additionally with the API
20 C AUX (V4.0).
MALDI-TOF MS yeast identiﬁcation with the Bruker
MALDI Biotyper 2.0 system
For yeast identiﬁcation with the MALDI BioTyper 2.0 system
(Bruker Daltonics), cells of approximately ﬁve colonies from
Sabouraud agar plates were suspended in 300 lL of water
and inactivated by addition of 900 lL of 96% ethanol [9].
The cells were spun down, and the pellet was air-dried at
room temperature, resuspended in 50 lL of 70% formic
acid, and extracted by addition of an equal volume of aceto-
nitrile and thorough mixing. Cellular debris was removed by
centrifugation (17 000 · g for 2 min), and 1 lL of the clear
supernatant was spotted onto a polished steel carrier,
allowed to dry, overlaid with 1 lL of HCCA matrix (satu-
rated solution of a-cyano-4-hydroxycinnamic acid in 50%
acetonitrile, 2.5% triﬂuoroacetic acid; Bruker Daltonics) and
allowed to dry again.
Measurement was performed with the MALDI BioTyp-
er 2.0 (library version 3.0) and FlexControl software on a
Microﬂex LT20 mass spectrometer (20-Hz nitrogen laser),
using a bacterial test standard (Bruker Daltonics) as a molec-
ular mass standard. Spectra were detected in positive linear
mode, with a mass range of 2–20 kDa. The intensity of the
laser was controlled by the FlexControl software driven in
automatic mode, at the settings recommended by the manu-
facturer. Only species identiﬁcations with scores >2.000
were accepted, and proposed identiﬁcations at the genus
level only were rejected.
MALDI-TOF MS yeast identiﬁcation with the AnagnosTec
Saramis system
For yeast identiﬁcation with the Saramis system (Spectral
Archive and Microbial Identiﬁcation System; AnagnosTec),
cells from a single colony on a Sabouraud agar plate
were directly applied onto the steel carrier, dried for a short
time (approximately 2 min) and lysed by suspension in 0.5 lL
of 25% formic acid. The sample was allowed to air-dry at room
temperature, overlaid with 1 lL of HCCA matrix (saturated
solution of a-cyano-4-hydroxycinnamic acid in acetonitrile/eth-
anol/water 1 : 1 : 1 acidiﬁed with 3% v/v triﬂuoroacetic acid)
(AnagnosTec) and again allowed to air-dry.
Measurement was performed on an AXIMA Assurance
platform (Shimadzu Biotech, Duisburg, Germany) in positive
linear mode, with a mass range of 2–20 kDa, using Escherichia
coli strain CCUG 10979 as a molecular mass standard. The
intensity of the 50-Hz nitrogen laser was under the control
of the acquisition software, at the settings recommended by
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the manufacturer. Only hits within the Superspectra database
(Saramis Premium, version 3.3.1) with scores >80% were
accepted, and identiﬁcations proposed from the single-spec-
trum database were excluded.
rDNA sequencing
For sequencing of the ITS2 rDNA region, fungal DNA from
a single large colony was isolated with the QIAamp DNA
Mini Kit (Qiagen, Hilden, Germany). The ITS2 rDNA region
was ampliﬁed [18], and the product was sequenced (SeqLab,




In total, for the 1192 isolates examined, the overall success
rate was >96% for each of the three individual methods
(Table 3a). For 1134 isolates, all three procedures led to a
correct species identiﬁcation (95.1%), leaving 58 strains for
which at least one of the methods repeatedly gave either a
wrong or no identiﬁcation (Table 2). All isolates of C. dublini-
ensis (n = 8), C. glabrata (n = 272), Candida tropicalis (n = 88),
Candida parapsilosis (n = 105), Cryptococcus neoformans
(n = 7), Pichia anomala (n = 5), P. norvegica (n = 5), Pichia jadi-
nii (n = 1), Trichosporon asahii (n = 4), and Yarrowia lipolytica
(n = 1) were recognized correctly by all methods. With our
approach, one isolate could not be identiﬁed at the species
level, and three further isolates showed slight nucleotide dif-
ferences from other known species and therefore could not
be fully classiﬁed. They were treated as separate species in
the context of this study.
For a more detailed data analysis, the tested isolates were
separated into several distinct subsets on the basis of their
representation status in the databases of the respective
method, e.g. if the species was listed on the code list for
API 20 C AUX/ID 32 C identiﬁcation, or reference spectra
(BioTyper 2.0)/’superspectra’ (Saramis) were present in the
MALDI-TOF MS databases. Consequently, an ‘unknown’
result could be considered to be a correct identiﬁcation for
isolates not present in a database, and any other identiﬁca-
tion could be considered to be a false identiﬁcation for that
particular species.
TABLE 2. Isolates with at least one
false or missing identiﬁcation
Species n Classical ID result Biotyper 2.0 ID Saramis ID
Candida albicans 1 missed 4 4
Saccharomyces cerevisiae 3 missed 4 4
Issatchenkia orientalis 2 missed 4 4
Pichia guilliermondii 2 4 missed 4
1 4 missed missed
Pichia farinosa 1 4 4 missed
Pichia fermentans 1 4 4 missed
Pichia membranefaciens 1 4 4 missed
Pichia cactophila 2 4 Pichia norvegica 4
2 Pichia norvegica Pichia norvegica missed
1 4 Pichia norvegica missed
Rhodotorula mucilaginosa 1 4 Rhodotorula glutinis 4
Candida rugosa 1 4 missed unknowna
7 4 4 unknowna
Kodamaea ohmeri 1 4 missed unknowna
1 4 4 unknowna
Galactomyces geotrichum 1 Geotrichum sp.b unknowna 4
Blastoschizomyces capitatus 1 4 unknowna unknowna
Geotrichum clavatum 3 Geotrichum sp.b unknowna unknowna
Candida metapsilosis 1 Candida parapsilosisa 4 Candida parapsilosisa
Candida orthopsilosis 8 Candida parapsilosisa 4 unknowna
Candida pararugosa 1 Candida boidiniia 4 unknowna
2 Candida rugosaa 4 unknowna
Pichia fabianii 1 Candida glabrataa unknowna unknowna
2 Candida albicansa unknowna unknowna
2 Pichia anomalaa unknowna unknowna
2 Pichia jadiniia unknowna unknowna
Candida bracarensis 1 Candida glabrataa unknowna unknowna
Candida viswanathii 1 Candida tropicalisa unknowna unknowna
Uncharacterized
basidiomycete
1 Cryptococcus humiculusa unknowna unknowna
Candida orthopsilosis-like 1 Candida parapsilosisa unknowna unknowna
Issatchenkia orientalis-like 1 Pichia cactophilaa Issatchenkia orientalisa Issatchenkia orientalisa
Candida glabrata-like 1 unknowna Candida glabrataa unknowna
4, isolates correctly identiﬁed; ‘missed’, isolates contained in the database but not recognized; ‘unknown’, isolates
not recognized and not in the database. Species names indicate misidentiﬁcations.
aNot in database.
bGenus level only.
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Isolates misclassiﬁed or not recognized but present in the
databases
The success rate for classiﬁcation was >99% by all
three methods when only those isolates were consid-
ered that were represented in the respective database
(Table 3b). Twenty-one species, representing 1148 isolates
(96%), should have been identiﬁable with all of the three
methods. The overall sensitivity in this subgroup was again
comparable, at >99%, for all three methods (Table 3c).
Several individual isolates could not be identiﬁed by at
least one of the methods (six by the classical methods,
ﬁve by the BioTyper and seven by the Saramis), and a few
individual isolates were misidentiﬁed by the classical
approach as well as the BioTyper. Among the latter, the
most notable were false identiﬁcations of P. cactophila as
P. norvegica, which are also difﬁcult to resolve biochemi-
cally [21]. No misclassiﬁcations were found within the
Saramis results among species contained in its database
(Table 2).
Classiﬁcation of isolates not contained in the respective
databases
Both MALDI-TOF MS methods each misidentiﬁed only two
single isolates absent from the respective database as a
wrong species (Table 2). In contrast, the biochemical
approach misidentiﬁed 30 isolates as a wrong species (includ-
ing four Galactomyces geotrichum and Geotrichum clavatum iso-
lates, which were classiﬁed at the genus level in the ID 32 C
test), instead of reporting them as ‘unknown’.
Success rates for the MALDI-TOF MS systems were
99.0% and 99.2%, respectively (Table 3d), but that for classi-
cal identiﬁcation was only 96.7% (Table 3d).
Strikingly, isolates of Pichia fabianii were (correctly) not
recognized by either MALDI-TOF MS system, and were mis-
classiﬁed as four different species biochemically (Table 2).
Discussion
In this study, we tested the suitability of the two commer-
cially available MALDI-TOF MS databases BioTyper 2.0 and
Saramis for rapid species identiﬁcation of yeasts in a clinical
diagnostic approach. Both systems were compared with a
conventional differentiation scheme on a set of 1192 clinical
isolates.
Independently of the geographical origin of the isolates
(data not shown), both MALDI-TOF MS systems demon-
strated an overall species identiﬁcation rate (97.6% and 96.1%,
respectively) that was comparable to the one obtained with
the biochemical tests (96.9%, Table 3a). A recent study on
bacterial isolates showed similar results [22].
Analysis of the isolates absent from the databases showed
that the MALDI-TOF MS systems were better able to recog-
nize these as ‘unknown’ (Tables 2 and 3), whereas they were
generally misidentiﬁed as closely related species with the
classical approach. Consequently, when we took ‘unknown’
as a correct prediction for isolates not represented in the
database, success rates rose to 99.0% and 99.5% with the
MALDI-TOF MS systems (Table 3d), but to only 97.0% with
the classical approach. This reduction of false identiﬁcations
clearly represents a clinically relevant advantage of MALDI-
TOF MS over biochemical differentiation.
Among the species contained in the respective databases,
each of the methods was unable to identify several individual
TABLE 3. Frequencies of classiﬁcation, misclassiﬁcation and non-recognition














Classical 36 1192 100.0 1155 30 7 96.9
Biotyper 2.0 36 1192 100.0 1163 8 21 97.6
Saramis 36 1192 100.0 1146 2 44 96.1
(b) Performance only on species in respective method database
Classical 25 1163 97.4 1155 2 6 99.3
Biotyper 2.0 27 1175 98.4 1163 6 5 99.0
Saramis 22 1152 96.6 1145 0 7 99.4
(c) Performance only on species contained in all three databases
Classical 21 1148 96.5 1140 2 6 99.3
Biotyper 2.0 21 1148 96.5 1138 6 4 99.1
Saramis 21 1148 96.5 1141 0 7 99.4
(d) Performance, total (including ‘unknown’ as the correct identiﬁcation for isolates absent from the database)
Classical 36 1192 100.0 1156 30 6 97.0
Biotyper 2.0 36 1192 100.0 1180 8 5 99.0
Saramis 36 1192 100.0 1186 2 7 99.5
Success rates were calculated from: (a) all isolates; (b) all isolates identiﬁable with the respective method; (c) isolates commonly identiﬁable with all three methods; and
(d) all isolates, including ‘unknown’ as true identiﬁcations for isolates not represented in the database.
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isolates. Furthermore, among isolates that were contained in
the respective databases, several individual isolates were mis-
identiﬁed by the classical approach, and fewer by the BioTyp-
er; no misclassiﬁcations were found within the Saramis results.
Apart from the different hardware, the systems were dif-
ferent in sample preparation (the BioTyper required prior
extraction of the yeasts, whereas for the Saramis system, cell
lysis was possible on the carrier plate) and the design of the
underlying databases: both databases were constructed from
sum spectra of multiple readings of single isolates, but the
Saramis system introduces an additional layer of ‘superspec-
tra’, containing only those peaks that are common to differ-
ent isolates of the same species. Two singular incidences
point to the diagnostic consequences resulting from the dif-
ferent approaches: three of seven strains of P. cactophila
were misclassiﬁed as P. norvegica by our classical approach.
With the BioTyper system, ﬁve of these were misclassiﬁed in
a similar fashion, but were either correctly identiﬁed or
missed completely with the Saramis system (Table 2).
Sequencing of the reference strains used for the BioTyper
database entry showed that these had previously been mis-
identiﬁed (Bruker Daltonics, personal communication), and a
correction in the database remedied the problem.
The existence of misidentiﬁed reference strains was also
seen during the differentiation of Candida rugosa and Candida
pararugosa with the Saramis system: here, the spectra of the
C. pararugosa isolates clustered together with that of the
C. rugosa reference strain, indicating a previous misidentiﬁca-
tion. As the ‘superspectra’ of the Saramis system are based
on mass peaks manually selected from non-identical strains
of a species, the problem had been noted during the con-
struction of C. rugosa and C. pararugosa ‘superspectra’ before,
and they had not been included in the database (AnagnosTec,
personal communication).
Taken together, our data suggest that the ‘superspectra’
of the Saramis system allow easier intrinsic quality control
than the single-strain spectra of the BioTyper. However, in
clinical routine, these differences are negligible, as the all true
pathogens were well recognized by both systems.
The increased resolution of MALDI-TOF MS also allowed
for separation of several clusters of closely related yeasts
that were indistinguishable by classical differentiation. The
clinical importance can be illustrated with the Candida
orthopsilosis/metapsilosis/parapsilosis cluster: here, different
drug susceptibility patterns have been observed [23,24].
Also, several isolates of P. fabianii were hidden among incor-
rect identiﬁcations by the classical approach, indicating that
this species may have been missed frequently in the past (see
also [16]). The biochemical misidentiﬁcation of P. fabianii as
P. anomala has recently also been observed by others [25],
and as P. anomala is mainly associated with neonates and
other paediatric patients [26,27] and instances of drug resis-
tance have been reported [28], a careful re-examination of
this cluster seems necessary.
Two factors could be improved for the routine use of
both MALDI-TOF MS systems in the future: ﬁrst (as also in
the classical scheme), neither system provides an automated
category ‘not in database’ for good spectra without matches,
leaving it to the user to evaluate whether to repeat the iden-
tiﬁcation by MALDI-TOF MS or to use another method (e.g.
PCR). Second, both systems have been established using Sab-
ouraud agar: it is not clear how the use of other agars (e.g.
CHROMagar) commonly in use for primary yeast cultivation
for the identiﬁcation of mixed yeast infections will inﬂuence
the outcome of MS-based species identiﬁcation.
Both MALDI-TOF MS methods allowed more precise spe-
cies identiﬁcation of yeasts in a fraction of the time needed
by the classical method. This was mainly because of the
reduced false identiﬁcation of isolates not contained in the
database, which also presented the major constraint in spe-
cies identiﬁcation. As the MALDI-TOF MS spectral databases
are more easily updated than biochemical methods, this will
lead to a rapid improvement in the underlying data and prob-
ably greatly diminish differences in the near future.
As the intrinsic resistance of yeasts to antifungal agents
is generally predictable from the species [4], it is likely
that the beneﬁt of the substantial time savings of this tech-
nology, together with the increased resolution, will improve
yeast diagnostics and have a profound impact on patient
survival.
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